[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365174-105":59,"doc-detail-365174-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","integrative-proteogenomic-characterization-reveals-therapeutic-targets-in-poorly-differentiated-and-anaplastic-thyroid-cancers","Integrative proteogenomic characterization reveals therapeutic targets in poorly differentiated and anaplastic thyroid cancers","","Poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC) are highly aggressive and heterogeneous, creating major barriers to effective treatment. This study performs deep, multi-scale analyses across genomic, proteomic, and phosphoproteomic data from 348 thyroid-cancer and 119 tumor-adjacent samples. Frequent mutations include TP53, TERT promoter, and additional drivers, while ribosome biogenesis emerges as a common ATC hallmark. Proteomic clustering defines three molecular subtypes with distinct signaling and immune infiltration patterns, and C5AR1 targeting synergizes with PD-1 blockade to enhance antitumor activity in ATC-derived tumors, supporting precision therapy opportunities.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integrative-proteogenomic-characterization-reveals-therapeutic-targets-in-poorly-differentiated-and-anaplastic-thyroid-cancers/365174/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integrative-proteogenomic-characterization-reveals-therapeutic-targets-in-poorly-differentiated-and-anaplastic-thyroid-cancers/365174.png","ImageObject",300,407,{"name":92,"@type":93},"Margaret","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What data types were integrated in this proteogenomic study of thyroid cancer?","Question",{"text":112,"@type":113},"The study integrates genomic, proteomic, and phosphoproteomic analyses using a multi-center thyroid cancer cohort of FFPE samples.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which mutations are reported as most frequent in PDTC and ATC?",{"text":117,"@type":113},"TP53, TERT promoter mutations, and additional drivers are reported as the most frequently mutated across PDTC and ATC.",{"name":119,"@type":110,"acceptedAnswer":120},"How do the identified ATC/PDTC subtypes differ, and what is a key therapeutic finding?",{"text":121,"@type":113},"Proteomic clustering defines three ATC/PDTC subtypes with distinct signaling and immune infiltration features. Targeting C5AR1 is reported to synergistically improve antitumor effects when combined with PD-1 blockade against ATC cell-derived tumors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},365174,1790658321,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},137451207643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Article [https://doi.org/10.1038/s41467-025-58910-3](https://doi.org/10.1038/s41467-025-58910-3)  \nIntegrative proteogenomic characterization reveals therapeutic targets in poorly differentiated and anaplastic thyroid cancers  \nReceived: 19 August 2024  \n\n| Accepted: 3 April 2025 |\n| --- |\n| |\n| Check for updates |\n\nZongfu Pan1,2,3,4,12, Zhuo Tan2,3,4,12, Ning Xu5,12, Zhenmei Yao5,12,  \nChuanming Zheng2,3,4, Jinbiao Shang6,7, Lei Xie8, Jiajie Xu2,3,4, Jiafeng Wang2,3,4, Liehao Jiang2,3,4, Xuhang Zhu6,7, Dingyi Yu1,3,4, Ying Li1, Yulu Che1, Yingying Gong2, Zhaoyu Qin 5, Yiwen Zhang1,3,4, Xiaozhou Zou 1,3,4, Tong Xu1,3,4,  \nZhenying Guo9, Tiefeng Jin2, Tiannan Guo 10, Wei Wang9, Wanyuan Chen9, Yaoting Sun 10, Weixin Wang11, Xiaojun Peng11, Changtian Yin2,3,4,  \nChen Ding 5 , Ping Huang 1,3,4  & Minghua Ge 2,3,4   \nPoorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC) present major challenges in treatment owing to extreme aggressiveness and high heterogeneity. In this study, deep-scale analyses spanning genomic, proteomic, and phosphoproteomic data are performed on 348 thyroid-cancer and119tumor-adjacent samples. TP53(48%), TERT promoter(36.5%), and (23%) are most frequently mutated in PDTC and ATC. Ribosome biogenesis isidentiﬁed as a common hallmark of ATC, and RRP9 silencing dramatically inhibits tumor growth. Proteomic clustering identiﬁed three ATC/PDTC subtypes. Pro-I subtype is characterized with aberrant insulin signaling and low immune cell inﬁltration, and Pro-II is featured with DNA repair signaling, while Pro-III harbors high frequency of TP53 and BRAF mutation and intensive C5AR1+ myeloid inﬁltration. Targeting C5AR1 synergistically improves antitumor effect of PD-1 blockade against ATC cell-derived tumors. These ﬁndings provide systematic insights into tumor biology and opportunities for drug discovery, accelerating precision therapy for virulent thyroid cancers.  \nThyroid cancer is one of the most common cancers with an estimated 586,202 new cases reported worldwide in 20201. Follicular thyroid cancer (FTC), medullary thyroid cancer (MTC), papillary thyroid cancer (PTC), poorly differentiated thyroid cancer (PDTC), and anaplastic thyroid cancer (ATC) are the major histological subtypes of thyroid cancer. PTC accounts for ~80% of all thyroid cancers and >90% of patients have a 10-year survival. In sharp contrast, though ATC and PDTC makeup5%–10%ofthyroid cancers, they are extremely aggressive subtypes with a median survival of only 0.5 and 3.2 years, respectively. The tumor-node-metastasis (TNM) classiﬁcation system generally classiﬁes patients with ATC as stage IV (A, B, or C) due to their universally  \npoor prognosis2, and most of them have unresectable or metastatic disease. ATC is featured with extensive local invasion and 15%– patients show distant metastasis at diagnosis. Unfortunately, there are no effective treatments for prolonging the survival of patients with ATC.  \nFundamental ﬁndings have delineated the molecular basis of ATC and PDTC aggressiveness. BRAFand RAS were demonstrated to be the  \nTP53, TERT promoter, and PI3K/AKT signaling were genomic hallmarksof ATC3. Compared with PDTC or other thyroid cancer subtypes, the  \ngiant cells, spindle cells, and epithelioid pathology rather than a pure  \nBRAF  \n50% of  \npredominant drivers of PDTC, while higher mutation frequencies of  \nhistology of ATC is heterogeneous and often displays a mixture of  \nA full list of afﬁliations appears at the end of the paper. e-mail: [chend@fudan.edu.cn](chend@fudan.edu.cn); [huangping@hmc.edu.cn](huangping@hmc.edu.cn); [geminghua@hmc.edu.cn](geminghua@hmc.edu.cn)  \npattern. Based on targeted next-generation sequencing, three genetically distinct subtypes of ATCs have been identiﬁed, and these subtypes have been proposed to evolve from PTC, FTC, and HCTC, mainly driven by BRAFV600E, NRAS, and PTEN/NF1/RB1 mutations, respectively4. Although the genomic and transcriptomic proﬁles of ATC and PDTC have ","cbCaia16novfBtps","https://ap.wps.com/l/cbCaia16novfBtps","pdf",6006032,"English","# Results\n## Overview of proteogenomic characterization in thyroid cancer cohort\n## Molecular signatures across genome, protein, and phosphoproteome\n## Proteomic clustering into ATC/PDTC subtypes\n## Therapeutic vulnerabilities and synergy with PD-1 blockade","[{\"question\":\"What data types were integrated in this proteogenomic study of thyroid cancer?\",\"answer\":\"The study integrates genomic, proteomic, and phosphoproteomic analyses using a multi-center thyroid cancer cohort of FFPE samples.\"},{\"question\":\"Which mutations are reported as most frequent in PDTC and ATC?\",\"answer\":\"TP53, TERT promoter mutations, and additional drivers are reported as the most frequently mutated across PDTC and ATC.\"},{\"question\":\"How do the identified ATC/PDTC subtypes differ, and what is a key therapeutic finding?\",\"answer\":\"Proteomic clustering defines three ATC/PDTC subtypes with distinct signaling and immune infiltration features. Targeting C5AR1 is reported to synergistically improve antitumor effects when combined with PD-1 blockade against ATC cell-derived tumors.\"}]","Integrative proteogenomic characterization reveals therapeutic targets in poorly differentiated and anaplastic thyroid cancers | PDF",1790160255,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f07dc21ea0680bf069b3f99581b74ce4.webp",983,1305,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ed9e305f8c9a12318d5f577d57c8ffa9.webp",982,1304,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f10e0157b2f2a773443bf9c12ebcc342.webp",981,1303,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/556f5b617823d8747976f28c09553f80.webp",980,1301]